Atle Fund Management AB — 13F Holdings & Portfolio
CIK 1381843 · latest 13F-HR filed 2026-07-24
Atle Fund Management AB manages $371.7M in 13F-reported U.S. long-equity assets across 39 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are LLY (9.62%), MRK (6.55%), JNJ (5.84%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 3 new positions and exited 3; 21 existing positions rose in reported value and 9 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-07-24
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
Portfolio map
Q2 26Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.
Sector mix
% of 13F valueSectors from each company's SIC code; funds and ETFs grouped separately.
Biggest buys and sells
Q1 26 → Q2 26Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.
13F assets and positions
4 quartersTotal reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.
Top positions over time
reported valueThe eight largest current positions, valued at each quarter end.
Concentration
top 10 = 48%Cumulative share of the portfolio held in the largest N positions.
| Name | Title / Status | Ownership | Type |
|---|
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- JOHNSON & JOHNSON$9.8M +81.7%
- ELI LILLY & CO$8.9M +33.2%
- CVS HEALTH CORP$5.8M +63.1%
- ABBVIE INC$5.8M +55.9%
- REVOLUTION MEDICINES INC$4.6M +50.8%
Top Trims
- BRIDGEBIO PHARMA INC-$2.6M -21.9%
- BOSTON SCIENTIFC-$2.6M -29.4%
- BEONE MEDICINES LTD-ADR-$2.1M -17.4%
- VERTEX PHARMACEUTICALS INC-$1.7M -14.9%
- CELCUITY INC-$1.7M -32.2%
Exited Positions
Show all 3 →Atle Fund Management AB Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | ELI LILLY & CO | LLY | 532457108 | $35.8M | 9.62% | 29,821 | SH |
| 2 | MERCK & CO. INC | MRK | 58933Y105 | $24.3M | 6.55% | 189,357 | SH |
| 3 | JOHNSON & JOHNSON | JNJ | 478160104 | $21.7M | 5.84% | 85,425 | SH |
| 4 | ABBVIE INC | ABBV | 00287Y109 | $16.2M | 4.35% | 64,325 | SH |
| 5 | CVS HEALTH CORP | CVS | 126650100 | $15.1M | 4.07% | 146,102 | SH |
| 6 | THERMO FISHER SCIENTIFIC CORP | TMO | 883556102 | $14.0M | 3.76% | 27,859 | SH |
| 7 | REVOLUTION MEDICINES INC | RVMD | 76155X100 | $13.7M | 3.68% | 73,077 | SH |
| 8 | BIOGEN INC | BIIB | 09062X103 | $13.6M | 3.65% | 62,781 | SH |
| 9 | NEUROCRINE BIOSCIENCES INC | NBIX | 64125C109 | $12.3M | 3.31% | 72,898 | SH |
| 10 | MIRUM PHARMACEUTICALS INC | MIRM | 604749101 | $11.8M | 3.17% | 100,807 | SH |
| 11 | ALKERMES PLC | ALKS | G01767105 | $11.2M | 3.01% | 213,329 | SH |
| 12 | IONIS PHARMACEUTICALS INC | IONS | 462222100 | $10.9M | 2.93% | 137,131 | SH |
| 13 | BEONE MEDICINES LTD-ADR | ONC | 07725L102 | $10.0M | 2.70% | 35,180 | SH |
| 14 | INTUITIVE SURGICAL INC | ISRG | 46120E602 | $9.8M | 2.64% | 24,656 | SH |
| 15 | STRYKER CORPORATION | SYK | 863667101 | $9.5M | 2.57% | 30,283 | SH |
| 16 | VERTEX PHARMACEUTICALS INC | VRTX | 92532F100 | $9.5M | 2.56% | 19,131 | SH |
| 17 | EDWARDS LIFESCIENCES CORP | EW | 28176E108 | $9.3M | 2.51% | 103,230 | SH |
| 18 | BRIDGEBIO PHARMA INC | BBIO | 10806X102 | $9.3M | 2.50% | 124,707 | SH |
| 19 | KRYSTAL BIOTECH, INC | KRYS | 501147102 | $8.9M | 2.40% | 24,019 | SH |
| 20 | CENCORA INC | COR | 03073E105 | $8.8M | 2.37% | 31,126 | SH |
| 21 | NEWAMSTERDAM PHARMA CO NV | NAMS | N62509109 | $8.4M | 2.27% | 248,848 | SH |
| 22 | ABIVAX SA | ABVX | 00370M103 | $7.8M | 2.09% | 58,170 | SH |
| 23 | INCYTE CORP | INCY | 45337C102 | $6.5M | 1.74% | 56,953 | SH |
| 24 | IRHYTHM TECHNOLOGIES INC | IRTC | 450056106 | $6.4M | 1.73% | 54,102 | SH |
| 25 | BOSTON SCIENTIFC | BSX | 101137107 | $6.2M | 1.68% | 146,381 | SH |
| 26 | INSMED INC | INSM | 457669307 | $6.2M | 1.67% | 58,378 | SH |
| 27 | TANGO THERAPEUTICS INC | TNGX | 87583X109 | $6.2M | 1.67% | 198,557 | SH |
| 28 | GILEAD SCIENCES INC | GILD | 375558103 | $5.8M | 1.57% | 46,142 | SH |
| 29 | CARDINAL HEALTH INC | CAH | 14149Y108 | $5.6M | 1.51% | 23,630 | SH |
| 30 | ORUKA THERAPEUTI | ORKA | 687604108 | $5.2M | 1.41% | 54,886 | SH |
| 31 | SPYRE THERAPEUTICS INC | SYRE | 00773J202 | $5.1M | 1.36% | 57,030 | SH |
| 32 | DEXCOM INC | DXCM | 252131107 | $4.8M | 1.30% | 71,846 | SH |
| 33 | BICARA THERAPEUTICS INC | BCAX | 055477103 | $4.3M | 1.16% | 145,657 | SH |
| 34 | IDEAYA BIOSCIENCES INC | IDYA | 45166A102 | $3.5M | 0.95% | 94,478 | SH |
| 35 | CELCUITY INC | CELC | 15102K100 | $3.5M | 0.94% | 33,313 | SH |
| 36 | DISC MEDICINE INC | IRON | 254604101 | $3.2M | 0.86% | 43,682 | SH |
| 37 | PYXIS ONCOLOGY INC | PYXS | 747324101 | $2.9M | 0.78% | 966,459 | SH |
| 38 | COMPASS THERAPEUTICS INC | CMPX | 20454B104 | $2.3M | 0.62% | 1,048,593 | SH |
| 39 | JADE BIOSCIENCES | JBIO | 008064206 | $2.0M | 0.53% | 88,556 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-07-24 | $371.7M | 39 | 0001381843-26-000005 |
| 2026-03-31 | 2026-05-11 | $309.7M | 39 | 0001381843-26-000004 |
| 2025-12-31 | 2026-02-06 | $313.4M | 39 | 0001381843-26-000002 |
| 2025-09-30 | 2025-11-04 | $27.0M | 38 | 0001381843-25-000009 |
STOCKHOLM, V7 SE-114 57